Core Insights - Clarivate is experiencing a "positive inflection point" after meeting its full-year financial guidance for the first time since 2019, with nearly 2% organic annual contract value (ACV) growth and over $1 billion in adjusted EBITDA for 2025 [2][5][6] Financial Performance - For 2025, Clarivate reported nearly 2% organic ACV growth, improved organic recurring revenue mix to 88%, and generated over $1 billion in adjusted EBITDA along with $365 million in free cash flow [6][7] - Fourth-quarter revenue was $617 million, with full-year revenue totaling $2.455 billion, primarily influenced by inorganic changes due to divestitures [7] - Adjusted diluted EPS for the fourth quarter was $0.20, reflecting a $0.02 sequential increase, with operating cash flow of $160 million [8] AI Strategy - Clarivate is implementing an "Intelligence Amplified" strategy, focusing on AI assistants and workflow agents, with 97% of revenue derived from proprietary solutions enhanced by AI [2][3][9] - The company has launched 10 AI assistants and AI-native solutions, now utilized by over 4,000 institutions, and expects to release more than 10 additional AI solutions in the coming year [10][12] Business Segments - The Life Sciences & Healthcare (LS&H) business is under review for potential sale to enhance focus on Academia & Government (A&G) and Intellectual Property (IP) markets, although 2026 guidance assumes LS&H will be retained for the full year [4][16] - In A&G, the segment achieved 2% organic ACV growth despite funding challenges, with a shift towards a recurring revenue model [10] - The IP segment is undergoing a turnaround with new leadership and AI product launches, showing a 270 basis points year-over-year improvement in annuities revenue [11] Capital Allocation and Leverage - Clarivate's capital allocation strategy includes $225 million in share repurchases and $200 million in bond retirements, maintaining net leverage at approximately four times [14][15] - For 2026, the company aims for 2-3% organic ACV growth, margin expansion to nearly 43%, and a free cash flow target of approximately $400 million [3][17]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [18] - Q4 net income improved by $195 million year-over-year to $3 million, and full-year net income improved by $436 million, primarily due to the absence of prior year impairment charges [18] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [18] - Operating cash flow for Q4 was $160 million, reflecting a $19 million improvement compared to the previous year [19] - Free cash flow for the full year reached $365 million, representing approximately 2% growth over the prior year [22] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now from proprietary solutions [12] - The Intellectual Property business saw a 270 basis point year-over-year improvement in annuities revenue, indicating stronger execution [15] - Life Sciences & Healthcare reported consistent quarterly ACV growth, with 11,000 global active users leveraging AI research assistants [15] Market Data and Key Metrics Changes - The company expects organic annual contract value growth of 2%-3% for 2026, an acceleration from previous years [16] - Recurring organic revenue is targeted to grow by 1%-2% in 2026, an improvement of nearly 100 basis points compared to the previous year [16] - The company anticipates a modest foreign exchange translation benefit of $10 million for the year [26] Company Strategy and Development Direction - The company is focused on selling its Life Sciences & Healthcare business to enhance value creation and strengthen its balance sheet [6][12] - The strategy emphasizes AI as an amplifier of existing business models rather than a disruption, with 97% of revenue derived from proprietary solutions [7][8] - The company plans to continue investing in AI innovations and has launched multiple AI-powered products to enhance customer workflows [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, citing strong cash generation and stable revenue retention rates of 93% [5] - The outlook for 2026 includes expectations for continued improvement in key financial metrics and a focus on maximizing shareholder value through disciplined capital allocation [17] - Management acknowledged market concerns regarding AI disruption but emphasized the proprietary nature of their offerings as a competitive advantage [7] Other Important Information - The company has initiated a process to sell its Life Sciences & Healthcare segment, which is expected to allow for greater focus on the A&G and IP markets [6] - The company has successfully transitioned its business model towards a more predictable subscription-based model, increasing organic recurring revenue mix to 88% [11] Q&A Session Summary Question: Monetization model for subscriptions and AI products - Management indicated that they continue to use AI to protect and grow subscription revenue, with various pricing models based on institution size [34][35] Question: Revenue from proprietary data and tech-enabled workflows - Management clarified that 97% of revenue comes from proprietary data, with significant value derived from curation and integration into customer workflows [42][43] Question: Considerations for selling Life Sciences and Healthcare business - Management stated that the decision was part of a broader value creation plan aimed at enhancing operational focus and shareholder value [50][51] Question: Strategic synergies between IP and A&G segments - Management highlighted the benefits of shared content and technology platforms between the IP and A&G segments, indicating potential for further collaboration [55][56] Question: Returning IP segment to organic revenue growth - Management expressed confidence in the IP segment's turnaround, citing improvements in annuities revenue and ongoing product innovation [61][63] Question: Capital allocation priorities - Management emphasized a focus on deleveraging while also considering stock buybacks, balancing between debt repayment and shareholder returns [67][68] Question: Price realization and revenue growth composition - Management noted that improvements in ACV and recurring revenue growth are primarily driven by volume rather than price increases [71][72]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $617 million, bringing the full year total to $2.455 billion, with changes driven entirely by inorganic factors due to business disposals [18] - Full year net income improved by $436 million compared to the previous year, primarily due to the absence of non-cash impairment charges and lower income tax and interest expenses [18] - Adjusted diluted EPS increased by $0.02 sequentially to $0.20 [18] - Operating cash flow for Q4 was $160 million, reflecting a $19 million improvement year-over-year [19] - Free cash flow for the full year reached $365 million, representing approximately 2% growth over the prior year [22] Business Line Data and Key Metrics Changes - The Academia and Government segment achieved 2% organic ACV growth, with 93% of revenue now coming from proprietary solutions [12] - The Intellectual Property business saw a 270 basis points year-over-year improvement in annuities revenue, indicating stronger execution [15] - Life Sciences & Healthcare reported significant adoption of AI solutions, with 11,000 global active users leveraging AI research assistants [15] Market Data and Key Metrics Changes - The company expects organic annual contract value growth of 2%-3% for 2026, an acceleration from previous years [16] - Recurring organic revenue is targeted to grow by 1%-2% in 2026, an improvement of nearly 100 basis points compared to the previous year [16] - The company anticipates a modest foreign exchange translation benefit of $10 million for the year [26] Company Strategy and Development Direction - The company is focusing on selling its Life Sciences & Healthcare business to enhance value creation and strengthen its balance sheet [6][12] - The strategy emphasizes AI as an amplifier of existing business models rather than a disruption, with 97% of revenue derived from proprietary assets [7][8] - The company aims to optimize its business model and improve sales execution, with a focus on innovation and product development [11][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve 10% free cash flow growth in 2026, supported by strong cash generation and stable revenue retention rates [5] - The management acknowledged market concerns regarding AI disruption but emphasized the proprietary nature of their business as a competitive advantage [7] - The outlook for the Intellectual Property segment is increasingly positive, with expectations of returning to organic revenue growth [16] Other Important Information - The company has launched a process to sell its Life Sciences & Healthcare business, which is expected to focus operational execution on A&G and IP segments [6][12] - The company has introduced 12 major products and AI-powered features in 2025, strengthening its market position [11] Q&A Session Summary Question: Can you talk about your monetization model for your subscriptions and for the new AI products? - The company continues to use AI to protect and grow its subscription revenue, with upsell opportunities for existing products and a shift towards more subscription-based models [34][36] Question: Can you explain the 97% of revenue coming from proprietary data? - The company clarified that 97% of its business derives from proprietary data, with a significant portion coming from information services and enterprise software [42][43] Question: What were the key considerations for initiating a sale process for the Life Sciences and Healthcare business? - The decision was based on the goal of creating shareholder value and focusing on operational execution across A&G and IP segments [50][51] Question: What will it take to return the IP segment to organic revenue growth? - Management highlighted the importance of product innovation and market recovery as key drivers for returning the IP segment to growth [62][66] Question: Can you provide color on capital allocation priorities? - The company plans to focus on deleveraging this year while also considering stock buybacks, given the attractive free cash flow yield [69][70] Question: Can you speak to the composition of ACV and recurring revenue growth in 2025? - The company noted that improvements in ACV and recurring organic growth were primarily driven by volume rather than price realization [72][73]